Premium
Acalabrutinib With Obinutuzumab in Treatment‐Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3‐Year Follow‐Up
Author(s) -
Woyach J.,
Rogers K.A.,
Bhat S.,
Blachly J.,
Jianfar M.,
Hamdy A.,
Frigault M.M.,
Izumi R.,
Munugalavadla V.,
Quah C.S.,
Wang M.H.,
Byrd J.C.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.26_2630
Subject(s) - medicine , obinutuzumab , adverse effect , gastroenterology , rash , refractory (planetary science) , chronic lymphocytic leukemia , fludarabine , nausea , leukemia , cyclophosphamide , chemotherapy , physics , astrobiology